Association between the Pro12Ala Polymorphism of Peroxisome Proliferator-Activated Receptor Gamma 2 and Inflammatory Bowel Disease A Meta-Analysis 英文参考文献.docVIP

下载本文档

4
0
约3.62万字
约 9页
2017-05-11 发布于上海
举报
版权申诉

Association between the Pro12Ala Polymorphism of Peroxisome Proliferator-Activated Receptor Gamma 2 and Inflammatory Bowel Disease A Meta-Analysis 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Association between the Pro12Ala Polymorphism of Peroxisome Proliferator-Activated Receptor Gamma 2 and Inflammatory Bowel Disease A Meta-Analysis 英文参考文献

AssociationbetweenthePro12AlaPolymorphismof PeroxisomeProliferator-ActivatedReceptorGamma2 andInflammatoryBowelDisease:AMeta-Analysis Zhi-FengZhang1*.,NingYang2.,GangZhao1,LeiZhu1,Li-XiaWang1 1DepartmentofGastroenterology,TheFirstAffiliatedHospitalofDalianMedicalUniversity,Dalian,China,2DepartmentofNephrology,TheFirstAffiliatedHospitalof DalianMedicalUniversity,Dalian,China Abstract Background:Peroxisomeproliferator-activatedreceptorgamma(PPARc),anuclearreceptor,hasbeenimplicatedplayinga role in the development of inflammatory bowel disease (IBD). However, previous studies evaluating the association between the PPARc2 Pro12Ala polymorphism and IBD are inconsistent. We performed a meta-analysis to determine whetherthePPARc2Pro12AlamutationwasassociatedwiththepresenceofIBD. MethodsandFindings:Electronicdatabasesweresearchedforcase-controlstudiesevaluatingtheassociationbetweenthe Pro12AlamutationandthepresenceofIBD.EffectsweresummarizedwiththemethodsrecommendedbytheCochrane Collaboration. A total of 7 studies including 1002 ulcerative colitis (UC) cases, 1090 Crohn`s disease (CD) cases and 1983 controlswereinvolvedinthismeta-analysis.Intheoverallanalysis,nosignificantassociationofthispolymorphismwithUC or CD was found. In the subgroup analyses in different populations, AlaAla genotype seemed to protect the European CaucasianpopulationagainstthedevelopmentofCD(ProvsAla:OR=1.135,95%CI=0.951–1.354,P=0.162,Bon=1.000; ProProvsProAla:OR=1.042,95%CI=0.852–1.273,P=0.690,Bon=1.000;ProProvsAlaAla:OR=2.379,95%CI=1.110–5.100, P=0.026, Bon=0.156; ProAla vs AlaAla: OR=2.315, 95%CI=1.064–5.037, P=0.034, Bon=0.204; Pro homozygotes vs Ala positives: OR=1.094, 95%CI=0.899–1.330, P=0.371, Bon=1.000; Pro positives vs Ala homozygotes: OR=2.360, 95%CI=1.103–5.053,P=0.027,Bon=0.162;heterozygotesvsallhomozygotes:OR=0.976,95%CI=0.799–1.192,P =0.809, Bon=1.000).TherewasnosignificantassociationofthispolymorphismwithUCorCDintheEastAsianpopulationandthe Turkishpopulation. Conclusion:AlaAlag